The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.

FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...

U.S. stocks open with little chane as investors anxiously await more news on Trump's tariff plans, Nvidia's earnings and ...

Hims & Hers Health (NYSE:HIMS) shares plunged early Tuesday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin. Earnings per ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.